Track market-moving stories before they get noisy

On July 24, 2026, Baxter International Inc (BAX) shares rose 3.4% to a current price of $22.40. This price is situated within a 52-week range of $15.73 to $29.3

The market expects Baxter International (BAX - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis drug and medical device maker is expected to post quarterly earnings of $0.36 per share in its upcoming report, which represents a year-over-year change of -39%.

Revenues are expected to be $2.79 billion, down 0.6% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.53% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Baxter?For Baxter, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.99%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Baxter will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Baxter would post earnings of $0.31 per share when it actually produced earnings of $0.36, delivering a surprise of +16.13%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Baxter doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerAnother stock from the Zacks Medical - Products industry, Tilray Brands, Inc. (TLRY - Free Report) , is soon expected to post loss of $0.02 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -110%. Revenues for the quarter are expected to be $258.13 million, up 15% from the year-ago quarter.

The consensus EPS estimate for Tilray Brands has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -100.00%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Tilray Brands will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.bax.

Baxter International Inc. NYSE:BAX , a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company’s progress and refreshed approach to advancing a sustainable and responsible business model.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622741106/en/

Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

“As we shape Baxter’s next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, president and chief executive officer. “The progress captured in this report is the result of the dedication of Baxter colleagues who bring our Mission to Save and Sustain Lives to life every day. Their commitment continues to drive Baxter forward and strengthen our ability to create lasting value for those we serve.”

The report highlights Baxter’s progress across key priorities in 2025, including strengthening collaboration with healthcare partners to improve patient care, driving operational efficiency and environmental sustainability, and advancing a culture of safety and well-being for employees. The company and the Baxter Foundation also continued investing in communities worldwide, including more than $32 million in contributions through strategic partnerships, product donations and employee matching gifts. Building on this progress and more than 30 years of environmental reporting, the company has refined its sustainability strategy and governance approach.

Refreshed Sustainability Strategy and Governance

Aligned to Baxter Growth and Performance System (GPS), which was introduced in 2025, the company strengthened its approach to sustainability governance with the establishment of its first chief sustainability officer role and newly created sustainability team, enhancing coordination and accountability across the enterprise.

Informed by the company’s recent double materiality assessment, Baxter has refreshed both its sustainability strategy and reporting to reflect a more forward-looking approach to long-term value creation for its stakeholders. The company’s refined sustainability strategy centers on three core areas: Deliver Sustainable Healthcare, Advance Climate & Resiliency, and Champion People & Communities. The refreshed areas of focus led to a new set of targets designed to drive measurable progress, replacing the 2030 commitments previously established. New targets include:

Net-Zero greenhouse gas emissions (GHG) across Scope 1 and Scope 2 by 2050, aligned with a 1.5⁰ Celsius science-based target 100% renewable electricity by 2040 80% of supplier spend in priority categories with suppliers that have science-based targets by 2030 100,000 employee volunteer hours by 2031, along with a previously established goal to invest $275 million by 2030 in underserved communities The sustainability strategy and goals continue to support the United Nations Sustainable Development Goals (SDG), with particular emphasis on advancing health and well‑being (SDG 3), water stewardship (SDG 6), responsible consumption (SDG 12), and climate action (SDG 13).

“When I joined Baxter as its first chief sustainability officer, I saw firsthand a culture grounded in care, collaboration and an unwavering commitment to patients,” said Renae Kezar, chief sustainability officer. “Sustainability is essential to enabling resilient healthcare delivery. Our sustainability strategy is designed to help ensure safe, reliable care while addressing the challenges facing healthcare and communities globally.”

Learn more and view the full report here.

About Baxter

At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician’s office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

This release includes forward-looking statements concerning Baxter's sustainability strategy described in the release, including newly launched sustainability targets. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology; the company’s operating results and financial condition have fluctuated and may fluctuate in the future, which may constrain the company’s ability to achieve its financial and other goals; the company has experienced in the past and may in the future experience manufacturing, sterilization, supply, or distribution difficulties; the effects of climate change, including legal, regulatory, or market measures related to climate change and other sustainability topics, could adversely affect the company’s business, results of operations, financial condition, and cash flows; the company is subject to laws and regulations globally, and its failure to comply with rapidly changing and increasingly divergent expectations of regulators in different jurisdictions could adversely impact the company; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter is a registered trademark of Baxter International Inc. or its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260622741106/en/

Key Takeaways Baxter is advancing a turnaround strategy focused on operational discipline and balance sheet repair.BAX saw strong Q1 growth in Advanced Surgery and Healthcare Technology despite broader weakness.Baxter faces pressure from Novum pump regulatory issues, margin compression and flat 2026 sales outlook. Baxter International (BAX - Free Report) entered 2026 focused on executing a broad turnaround strategy aimed at restoring growth, improving cash flow and strengthening operational discipline. While innovation initiatives, solid demand in select businesses and improving balance-sheet trends support its long-term outlook, regulatory challenges, margin pressure and continued weakness in certain core segments remain significant near-term headwinds.

Shares of this Zacks Rank #3 (Hold) company have gained 8.9% so far this year against the industry's 23.2% decline. The S&P 500 Index has jumped 8.6% during the same time frame.

BAX, with a market capitalization of $10.1 billion, is a global medical technology company providing items, such as infusion pumps and intravenous solutions. The company has an earnings yield of 9.2% compared with the industry's 3.3%. It anticipates earnings to improve 3.2% over the next five years.

Image Source: Zacks Investment Research

Positive Factors Driving ProspectsTurnaround Strategy Leading to Operational Progress: Baxter’s new management team is focused on stabilizing the business through its multi-pronged turnaround strategy centered on operational discipline, balance sheet repair and continuous improvement. The newly implemented Baxter Growth and Performance System (“GPS”) has already driven more than several improvement initiatives across the organization, helping improve execution, service reliability and working capital efficiency.

While the turnaround remains in its early stages, the framework introduces greater accountability by decentralizing P&L ownership and streamlining decision-making. This operational transformation should gradually restore consistency in revenue growth, improve margins and rebuild investor confidence.

Advanced Surgery and Healthcare Technology Remain Resilient: Despite broader operational challenges, Baxter continues to benefit from strong demand in several higher-growth businesses. Advanced Surgery revenues grew 10% in the first quarter of 2026, supported by steady procedure volumes and continued demand for hemostats and sealants across global markets.

In Healthcare Systems & Technologies, management highlighted strong momentum in Patient Support Systems and a healthy U.S. capital equipment order book, suggesting that hospital capital spending remains resilient despite broader macroeconomic uncertainty. However, continued execution will be critical to sustaining this momentum and offsetting ongoing challenges in other areas of the business.

These businesses represent strategically attractive segments with better growth profiles than legacy infusion-related products. This provides Baxter with an important growth cushion while management works through operational and regulatory challenges elsewhere in the portfolio.

Innovation Pipeline and AI Integration to Support Growth: Baxter is increasingly positioning innovation as a future growth catalyst, with management highlighting multiple recent product launches, including Dynamo smart hospital stretcher, Connex 360 connected-care platform, IV Verified automated medication labeling system and XR spine surgical table.

BAX is also aggressively integrating AI into both product development and internal operational workflows. Management emphasized that AI is already being deployed across connected-care infrastructure, manufacturing systems and quality workflows to improve clinical decision-making and operational efficiency. 

Baxter’s growing emphasis on incremental innovation and AI-driven healthcare solutions could gradually improve its competitive positioning and likely lead to stronger organic growth drivers.

Key ChallengesCore Business Performance Remains Weak: Baxter’s underlying operating performance remains weak. First-quarter revenues increased 3%, reportedly, but organic sales declined 1%, while adjusted EPS fell sharply 35% year over year to 36 cents. Multiple core businesses remain under pressure, including Medical Products & Therapy, Healthcare Systems Technology and Pharmaceuticals.

The company’s guidance for approximately flat organic sales growth for full-year 2026 indicates management does not expect meaningful near-term acceleration. While executives are emphasizing second-half improvement, current performance suggests Baxter is still operating well below its earnings potential.

Novum Infusion Pump Regulatory Problems Continues: The largest company-specific overhang remains Baxter’s ongoing Novum LVP infusion pump regulatory issue, which continues to prevent shipment and installation activity.

Management confirmed that the shipment hold is fully reflected in its full-year guidance. However, the company acknowledged that customer returns or product exchanges could still occur, creating an additional layer of uncertainty around future financial performance.

Although customer returns were immaterial during the first quarter, management repeatedly emphasized it remains prudent to maintain this risk assumption throughout 2026. The infusion pump portfolio accounts for less than 2% of total revenues, but the broader concern extends beyond lost pump sales into associated high-margin consumables, customer retention and reputational damage within hospital infusion systems.

Margin Compression Remains Severe: Baxter’s profitability deteriorated significantly during the quarter as multiple external and operational pressures simultaneously hit margins. Adjusted gross margin declined 500 basis points to 36.8%, while operating margin fell 390 basis points to 11%.

Management cited approximately $50 million of cost timing headwinds, higher tariff-related costs, elevated manufacturing expenses and lower production absorption. The company continues to estimate a full-year tariff-related headwind of approximately $80 million. In addition, it remains exposed to inflationary pressures from higher oil prices, freight expenses, semiconductor supply constraints and rising raw-material costs, all of which could weigh on profitability if they persist.

Although management expects roughly 500 basis points of second-half margin recovery, much of the pressure stems from external factors outside Baxter’s control. Sustained cost inflation could materially delay the company’s earnings recovery timeline.

Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $11.36 billion, indicating a 1% improvement from the previous year’s level.

The consensus mark for adjusted earnings per share (EPS) is pinned at $1.92, indicating a 15.4% decrease from the year-ago reported number. The consensus estimate for adjusted EPS has improved 1 cent in the past 60 days.

Stocks to ConsiderSome better-ranked stocks from the same medical industry are Align Technology (ALGN - Free Report) , West Pharmaceutical Services (WST - Free Report) and Cardinal Health (CAH - Free Report) .

Align Technology, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 10.3%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 7.80%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ALGN’s shares have gained 9.2% against the industry’s 4.2% decline so far this year.

West Pharmaceutical, currently carrying a Zacks Rank of 1, has an estimated long-term growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 19.37%.

West Pharmaceutical’s shares have gained 20.2% against the industry’s 4.2% decline year to date.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

CAH’s shares have gained 5.2% against the industry’s 4.2% decline so far this year.

Posted by Defense World Staff on Apr 8th, 2026

Shares of Baxter International Inc. (NYSE:BAX – Get Free Report) have been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $19.80.

Several equities analysts have recently weighed in on BAX shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Baxter International in a report on Wednesday, January 21st. The Goldman Sachs Group dropped their price objective on shares of Baxter International from $21.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Citigroup dropped their price objective on shares of Baxter International from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. Wells Fargo & Company dropped their price objective on shares of Baxter International from $21.00 to $19.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Finally, Evercore dropped their price objective on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday.

Check Out Our Latest Stock Report on BAX

Institutional Investors Weigh In On Baxter International A number of institutional investors and hedge funds have recently made changes to their positions in BAX. Greenhaven Associates Inc. acquired a new stake in shares of Baxter International in the 3rd quarter worth about $143,186,000. Dodge & Cox raised its holdings in shares of Baxter International by 10.1% in the 3rd quarter. Dodge & Cox now owns 57,396,370 shares of the medical instruments supplier’s stock worth $1,306,915,000 after acquiring an additional 5,274,750 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Baxter International by 477.6% in the 4th quarter. SG Americas Securities LLC now owns 1,725,251 shares of the medical instruments supplier’s stock worth $32,970,000 after acquiring an additional 1,426,547 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Baxter International by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock worth $257,174,000 after acquiring an additional 972,891 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Baxter International by 35.6% in the 4th quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock worth $65,216,000 after acquiring an additional 894,761 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Price Performance BAX stock opened at $16.62 on Wednesday. The company’s fifty day simple moving average is $18.87 and its 200 day simple moving average is $19.71. Baxter International has a 12-month low of $15.73 and a 12-month high of $32.68. The firm has a market cap of $8.58 billion, a price-to-earnings ratio of -8.98, a PEG ratio of 1.18 and a beta of 0.62. The company has a quick ratio of 1.56, a current ratio of 2.31 and a debt-to-equity ratio of 1.55.

Baxter International (NYSE:BAX – Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.09). Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The company had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.82 billion. During the same quarter in the prior year, the company posted $0.58 EPS. Baxter International’s revenue for the quarter was up 8.0% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. On average, analysts expect that Baxter International will post 2.48 earnings per share for the current year.

Baxter International Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Friday, February 27th were issued a dividend of $0.01 per share. The ex-dividend date was Friday, February 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is currently -2.16%.

Baxter International Company Profile (Get Free Report)

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

Featured Stories Five stocks we like better than Baxter International

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEContrasting WesBanco (NASDAQ:WSBC) and Home Bancorp (NASDAQ:HBCP)

NEXT HEADLINE »Archer Daniels Midland Company (NYSE:ADM) Given Consensus Rating of “Reduce” by Analysts

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents, at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo, taking place April 11-14, 2026 in New Orleans. New offerings include the AAT XR spine surgical table and the Dynam.

Posted by Defense World Staff on Apr 27th, 2026

Baxter International (NYSE:BAX – Get Free Report) and GN Store Nord (OTCMKTS:GNNDY – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Risk and Volatility Baxter International has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, GN Store Nord has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Analyst Recommendations This is a summary of current ratings for Baxter International and GN Store Nord, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baxter International 2 9 2 0 2.00 GN Store Nord 1 3 2 0 2.17 Baxter International currently has a consensus target price of $19.80, indicating a potential upside of 8.99%. Given Baxter International’s higher probable upside, equities research analysts clearly believe Baxter International is more favorable than GN Store Nord.

Insider and Institutional Ownership 90.2% of Baxter International shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability This table compares Baxter International and GN Store Nord’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Baxter International -8.51% 16.95% 5.62% GN Store Nord 3.97% 6.31% 2.29% Earnings and Valuation This table compares Baxter International and GN Store Nord”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Baxter International $11.24 billion 0.83 -$957.00 million ($1.85) -9.82 GN Store Nord $2.54 billion 0.91 $98.86 million $2.06 22.33 GN Store Nord has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than GN Store Nord, indicating that it is currently the more affordable of the two stocks.

Summary GN Store Nord beats Baxter International on 7 of the 13 factors compared between the two stocks.

About Baxter International (Get Free Report)

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

About GN Store Nord (Get Free Report)

GN Store Nord A/S provides hearing, audio, video, and gaming solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets, video cameras, and speakerphones for professional use and consumer products. It offers its products under the ReSound, Jabra, Beltone, Interton, Danavox, BlueParrott, FalCom, and SteelSeries brands. GN Store Nord A/S was founded in 1869 and is based in Ballerup, Denmark.

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEReviewing QuoteMedia (OTCMKTS:QMCI) and DeNA (OTCMKTS:DNACF)

NEXT HEADLINE »Comparing Establishment Labs (NASDAQ:ESTA) & Intelligent Bio Solutions (NASDAQ:INBS)

Wall Street expects a year-over-year decline in earnings on lower revenues when QuidelOrtho (QDEL - Free Report) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on May 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis medical diagnostics company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -67.6%.

Revenues are expected to be $618.07 million, down 10.8% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 58.33% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for QuidelOrtho?For QuidelOrtho, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -54.17%.

On the other hand, the stock currently carries a Zacks Rank of #5.

So, this combination makes it difficult to conclusively predict that QuidelOrtho will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that QuidelOrtho would post earnings of $0.43 per share when it actually produced earnings of $0.46, delivering a surprise of +6.98%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

QuidelOrtho doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical - Products industry, Baxter International (BAX - Free Report) , is soon expected to post earnings of $0.31 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of -43.6%. This quarter's revenue is expected to be $2.6 billion, down 0.8% from the year-ago quarter.

The consensus EPS estimate for Baxter has been revised 1.7% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -0.60%.

This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Baxter will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

On April 30, 2026, Baxter International Inc BAX released its 8-K filing detailing first-quarter 2026 results. Sales from continuing operations were $2.7 billion, up 3% on a reported basis and down 1% organically. U.S. GAAP diluted EPS from continuing operations was a loss of $0.03. Adjusted diluted EPS from continuing operations was $0.36. Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Headline results and estimate comparison Revenue was $2.70 billion. This is higher than the analyst estimate of $2.62 billion.

Adjusted diluted EPS from continuing operations was $0.36. This is higher than the analyst estimate of $0.11.

GAAP diluted EPS from continuing operations was a loss of $0.03. This is lower than the analyst estimate of $0.11.

For reference, current annual estimates call for EPS of $0.83 and revenue of $11,350.58 million.

Management commentary“Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter continues to take the decisive steps necessary to fulfill our commitment to delivering better and more consistent results for our shareholders. I want to thank our colleagues for their resilience, dedication and mission-driven focus to support the more than 350 million patients around the world who rely on us annually."Performance, challenges, and why they matter Top-line growth benefited from international strength and momentum in Advanced Surgery and Drug Compounding. U.S. revenue declined due to softer demand in infusion pumps and timing-related headwinds in Front Line Care. Segment operating margins compressed across all three operating groups. This reflects higher tariff and manufacturing costs, including lower absorption, which weighed on profitability.

The temporary shipment and installation hold of the Novum IQ Large Volume Pump reduced Infusion Therapies & Technologies sales. This matters because infusion pumps are a key component of Baxter’s recurring capital and disposables ecosystem. Persistent quality or regulatory issues could constrain placements and pull-through of related consumables, pressuring margins and cash generation in an industry where scale, product reliability, and service networks are competitive differentiators.

Metric Q1 2026 YoY Change / Notes Net sales (continuing) $2,701 million +3% reported; -1% organic U.S. sales $1,435 million -4% reported; -4% organic International sales $1,266 million +12% reported; +3% organic GAAP diluted EPS (cont.) $(0.03) vs $0.13 prior year Adjusted diluted EPS (cont.) $0.36 -35% year over year Adjusted operating income $297 million -24% year over year Analyst est. revenue $2,615.77 million Actual exceeded estimate Analyst est. EPS $0.11 Adjusted EPS exceeded estimateSegment trends and mix Medical Products & Therapies revenue was $1.285 billion. Reported growth was 2%. Organic growth declined 2%. Infusion Therapies & Technologies decreased 5% organically on lower infusion pump sales tied to the Novum IQ LVP shipment and installation hold and a tough comparison due to a one-time distributor build after Hurricane Helene last year. Advanced Surgery grew 10% organically on continued global demand.

Healthcare Systems & Technologies revenue was $705 million. Reported growth was flat. Organic growth declined 2%. Front Line Care decreased on order timing and planned portfolio exits. Care & Connectivity Solutions was approximately flat organically.

Pharmaceuticals revenue was $621 million. Reported growth was 7%. Organic growth was 1%. Drug Compounding rose 20% organically, partially offset by lower Injectables & Anesthesia, which declined 13% organically.

Profitability, cash, and key financial metrics On a GAAP basis, gross margin was $891 million, or 33.0% of sales, up 0.2 points year over year. Operating income was $66 million for a 2.4% margin. Interest expense was $66 million. The company reported a net loss from continuing operations of $17 million.

On an adjusted basis, diluted EPS from continuing operations was $0.36, down 35% year over year. Management cited an unfavorable prior-year comparison from an expense reclassification, along with higher tariffs and manufacturing costs, including lower absorption.

Segment operating margins contracted: Medical Products & Therapies to 14.5% from 19.3%, Healthcare Systems & Technologies to 9.4% from 13.2%, and Pharmaceuticals to 7.4% from 10.8%. Margin pressure is a focal metric for medical device companies, as it reflects pricing power, manufacturing efficiency, and product mix. Sustained cost inflation or lower plant utilization can dampen returns on invested capital in a capital-intensive industry.

The filing includes a reconciliation framework for free cash flow. The company defines free cash flow as operating cash flow less capital expenditures. This measure is widely watched in MedTech for funding R&D, quality remediation, and deleveraging, but specific cash flow figures were not included in the provided schedules.

Why this quarter matters for value investors Revenue exceeded expectations while adjusted EPS remained above consensus despite pronounced year-over-year compression. The divergence between GAAP and adjusted earnings underscores the impact of noncore items, tariffs, and manufacturing absorption. International growth and Advanced Surgery and Drug Compounding strength provided balance to U.S. declines tied to infusion pump constraints and order timing. Investors will likely focus on operational execution, cost controls, segment margin recovery, and the resolution of infusion pump-related constraints as key catalysts for fundamentals and valuation.

Selected segment and geography details Sales ($ millions) Q1 2026 Q1 2025 Reported YoY Organic YoY Medical Products & Therapies $1,285 $1,262 +2% -2% Healthcare Systems & Technologies $705 $704 0% -2% Pharmaceuticals $621 $581 +7% +1% U.S. sales $1,435 $1,490 -4% -4% International sales $1,266 $1,135 +12% +3%Analysis Baxter International Inc BAX delivered a revenue beat driven by international markets and resilient demand in Advanced Surgery and Drug Compounding. At the same time, margin compression across all segments and a GAAP loss highlight the cost environment and product-specific headwinds. Interest expense matched operating income on a GAAP basis, amplifying the sensitivity of net results to margin swings. The company’s adjusted figures point to core operating profitability but also to the urgency of cost containment and returning infusion pump volumes to normalized levels. For value-oriented investors, the quarter offers evidence of top-line stability with identifiable paths to improve margins, but execution on manufacturing efficiencies and product remediation appears central to closing the gap between adjusted and GAAP performance.

GuruFocus Valuation Check Based on GuruFocus’s proprietary valuation, Baxter International Inc BAX has a GF Value of $35.98 versus a current price of $16.90, implying the shares appear 53.0% undervalued. This suggests potential upside if fundamentals stabilize and margins improve toward historical norms.

The company’s GF Score is 57/100, which is classified as Average. Financial Strength is 4/10, indicating a moderate balance sheet with leverage and interest costs that investors should monitor. Profitability ranks 6/10, which points to reasonable core earnings power even as reported GAAP results were pressured. Growth ranks 3/10, reflecting subdued organic expansion and product-specific headwinds. Predictability is 1 star, signaling higher variability in results and lower earnings consistency. The Moat Score is 6/10, suggesting competitive advantages in core franchises but not insurmountable, especially amid cost and quality pressures.

Insider Activity shows no insider transactions in the last three months. A lack of notable buys or sells provides no incremental signal. For a deeper dive, visit the Baxter International Inc stock page on GuruFocus.

Explore the complete 8-K earnings release (here) from Baxter International Inc for further details.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Baxter International (BAX - Free Report) reported $2.7 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 2.9%. EPS of $0.36 for the same period compares to $0.55 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.6 billion, representing a surprise of +3.74%. The company delivered an EPS surprise of +15.42%, with the consensus EPS estimate being $0.31.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Pharmaceuticals- International: $441 million versus the two-analyst average estimate of $412.19 million. The reported number represents a year-over-year change of +14.3%.Geographic Net Sales- United States: $1.44 billion compared to the $1.42 billion average estimate based on two analysts.Net Sales- Other- International: $39 million compared to the $29.43 million average estimate based on two analysts. The reported number represents a change of +30% year over year.Net Sales- Infusion Therapies and Technologies- International: $455 million compared to the $434.6 million average estimate based on two analysts. The reported number represents a change of +11% year over year.Net Sales- Pharmaceuticals: $621 million compared to the $582.11 million average estimate based on four analysts. The reported number represents a change of +6.9% year over year.Net Sales- Advanced Surgery: $304 million versus the four-analyst average estimate of $291.29 million. The reported number represents a year-over-year change of +13.4%.Net Sales- Other: $90 million versus $80.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15.4% change.Net Sales- Front Line Care: $270 million compared to the $282.71 million average estimate based on four analysts. The reported number represents a change of -2.5% year over year.Net Sales- Drug Compounding: $320 million versus $274.25 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30.1% change.Net Sales- Care and Connectivity Solutions: $435 million compared to the $439.46 million average estimate based on four analysts. The reported number represents a change of +1.9% year over year.Net Sales- Medical Products and Therapies: $1.29 billion versus the four-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +1.8%.Net Sales- Healthcare Systems and Technologies: $705 million versus $722.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.1% change.View all Key Company Metrics for Baxter here>>>

Shares of Baxter have returned +0.7% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 323

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript